Result of Placing

SkinBioTherapeutics PLC

17 November 2023

 

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO OR WITHIN THE UNITED STATES, AUSTRALIA, NEW ZEALAND, CANADA, SOUTH AFRICA OR JAPAN, OR ANY MEMBER STATE OF THE EEA, OR ANY OTHER JURISDICTION WHERE, OR TO ANY OTHER PERSON TO WHOM, TO DO SO MIGHT CONSTITUTE A VIOLATION OR BREACH OF ANY APPLICABLE LAW OR REGULATION. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT.

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF THE MARKET ABUSE REGULATION (EU) 596/2014 WHICH FORMS PART OF UK LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 ("UK MAR"). IN ADDITION, MARKET SOUNDINGS (AS DEFINED IN UK MAR) WERE TAKEN IN RESPECT OF CERTAIN OF THE MATTERS CONTAINED IN THIS ANNOUNCEMENT, WITH THE RESULT THAT CERTAIN PERSONS BECAME AWARE OF SUCH INSIDE INFORMATION, AS PERMITTED BY UK MAR. UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN AND SUCH PERSONS SHALL THEREFORE CEASE TO BE IN POSSESSION OF INSIDE INFORMATION.

17 November 2023

SkinBioTherapeutics plc

("SkinBioTherapeutics" or the "Company")

Result of Placing

SkinBioTherapeutics plc (AIM: SBTX or the "Company") a life sciences company focused on skin health, is pleased to announce that, further to the announcement made on 16 November 2023 regarding the Placing (the "Launch Announcement"), it has raised £3.0 million (before expenses) via the placing of 15,908,298 Placing Shares at the Issue Price of 19 pence per share. The Placing was undertaken through an accelerated bookbuild and was materially oversubscribed.

The Placing Shares will, when issued, represent, in aggregate, circa 9.2 per cent. of the Company's issued ordinary share capital immediately prior to the Placing.

The Placing Price of 19 pence per Placing Share represents a 9.5 per cent. discount to the closing middle market price of 21 pence per Ordinary Share on 15 November 2023, being the last practicable dealing date prior to the publication of the Launch Announcement.

A further announcement will be made on 21 November 2023 announcing the result of the Retail Offer.

Application for Admission to Trading

The Placing Shares, when issued, will be fully paid and will rank pari passu in all respects with the Existing Ordinary Shares, including the right to receive all dividends and other distributions declared, made or paid after the date of issue.

Application has been made for the Placing Shares to be admitted to trading on AIM ("Admission"). It is expected that Admission will take place on or before 8.00 a.m. on 22 November 2023 and that dealings in the Placing Shares on AIM will commence at the same time.

The Placing is conditional upon, among other things, the Placing Agreement not being terminated in accordance with its terms and Admission becoming effective.

Capitalised terms used in this announcement (this "Announcement") have the meanings given to them in the Launch Announcement, unless the context provides otherwise.

For further information

SkinBioTherapeutics plc Stuart J. Ashman, CEO Manprit Randhawa, CFO	Tel: [phone]
Cavendish Securities plc (Nominated Adviser & Broker) Giles Balleny, Dan Hodkinson (Corporate Finance) Charlie Combe (Corporate Broking) Dale Bellis, Tamar Cranford-Smith (Sales)	Tel: [phone]
Instinctif Partners (financial press) Melanie Toyne-Sewell / Tim Field	Tel: [phone]    [e-mail]

 

END